Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cotadutide - AstraZeneca

Next Previous
X
Search
Drug Profile

Cotadutide - AstraZeneca

Alternative Names: MEDI 0382

Latest Information Update: 27 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; MedImmune
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 19 Apr 2024 AstraZeneca completes the phase II trial in Non-alcoholic steatohepatitis in USA, Argentina, Australia, Austria, Canada, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, New Zealand, South Africa, Spain, Taiwan, Thailand, Turkey and UK (SC) (EudraCT2021-005484-53) (NCT05364931)
  • 02 Oct 2023 Efficacy and adverse events data from a phase II trial in Type II diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
  • 05 Apr 2023 Discontinued - Phase-I for Liver disorders in USA (SC) (NCT05668936)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top